Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2025)
Historic Operating Leases for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Q3 2025 value amounting to $2.8 million.
- Rocket Pharmaceuticals' Operating Leases fell 1919.13% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 1919.13%. This contributed to the annual value of $3.3 million for FY2024, which is 958.63% up from last year.
- Rocket Pharmaceuticals' Operating Leases amounted to $2.8 million in Q3 2025, which was down 1919.13% from $2.9 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Operating Leases ranged from a high of $3.7 million in Q1 2024 and a low of $492000.0 during Q3 2022
- In the last 5 years, Rocket Pharmaceuticals' Operating Leases had a median value of $2.9 million in 2025 and averaged $2.2 million.
- As far as peak fluctuations go, Rocket Pharmaceuticals' Operating Leases tumbled by 4478.11% in 2022, and later soared by 50772.36% in 2023.
- Rocket Pharmaceuticals' Operating Leases (Quarter) stood at $905000.0 in 2021, then rose by 20.22% to $1.1 million in 2022, then surged by 173.25% to $3.0 million in 2023, then grew by 9.59% to $3.3 million in 2024, then fell by 15.35% to $2.8 million in 2025.
- Its Operating Leases was $2.8 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.1 million in Q1 2025.